Manufacturing

Pfizer is initiating a $500 million expansion of its Sanford campus with the construction of a 100,000-sf gene therapy facility. Supporting the creation of innovative treatments for genetic diseases, the project will feature advance manufacturing technologies for clinical and commercial-scale production of recombinant adeno-associated virus (rAAV) vectors. Accommodating 300 new employees, the facility will complement operations at the existing 628,000-sf Sanford complex and at the company's Chapel Hill and Kit Creek locations.

Raytheon is planning to build a 200,000-sf advanced manufacturing facility in McKinney, Texas. Supporting Raytheon's Space and Airborne Systems division, the center will act as a 'factory of the future' for the production of sensors, high-energy lasers, electro-optical devices, and surveillance and reconnaissance systems. Completion is expected in late 2020. Raytheon is a technology and innovation company specializing in defense, civil government, and cybersecurity solutions.

Amgen broke ground in late July of 2019 on a $200 million biomanufacturing center in West Greenwich, R.I. Featuring a highly flexible, modular design, the next-generation facility will leverage advanced technologies to reduce operational expenses, consume 80 percent less energy and water, and achieve a 75 percent decrease in carbon emissions.

HALIX is constructing a 72,000-sf cGMP facility at Leiden Bio Science Park in the Netherlands. Utilizing 1000-liter, single-use bioreactors, the five-story building will accommodate the development and manufacture of biopharmaceutical drug substances for clinical and commercial applications. Housing labs for process development, analytical development, and quality control, the structure will feature cleanrooms with unidirectional process flows with separate areas for protein manufacturing and the production of viral vaccines and viral vectors.

The University of Strathclyde is working with government and industry partners to create the £65 million National Manufacturing Institute Scotland in Inchinnan. The 124,000-sf facility will house the Digital Factory 2050, the Manufacturing Skills Academy, the Innovation Collaboratory, and a business forum.

ADC Bio completed construction of a £5 million bioconjugation cleanroom in July of 2019. Located within the company's 70,000-sf facility in Deeside in the United Kingdom, the GMP lab will support the commercial manufacture of innovative antibody-drug conjugates for the treatment of cancer. Designed and constructed by WHP Engineering, the project houses Grade C and D cleanrooms with four-zone HVAC systems for optimal environmental containment.

NorthStar Medical Radioisotopes completed construction in July of 2019 on a 20,000-sf production facility in Beloit, Wis. Featuring the company's RadioGenix® System, the project features state-of-the-art dissolution and source vessel filling equipment for the processing of molybdenum-99 (Mo-99) to support the creation of technetium-99m (Tc-99m) for diagnostic imaging applications. The facility also houses a quality control lab, an automated packaging line, and an advanced molybdenum recycling complex.

Swansea University is planning to construct the £30 million Center for Integrative Semiconductor Materials in Wales in the United Kingdom. The three-story, 46,500-sf facility will house cleanrooms, labs, and offices to support the creation of advanced semiconductor materials, processes, and technologies. Located on the Bay Campus, the multidisciplinary project will integrate manufacturing, research, and development operations as well as offering business incubation and workforce development opportunities.

Komatsu Mining Corp. is planning to construct a new $285 million headquarters campus in Milwaukee. The project will include an administrative office building with an integrated research center and a company museum. A 430,000-sf manufacturing facility will also be built on the 54-acre site. Groundbreaking will occur in late 2019 with completion expected in 2022. Subsequent phases of development may include the expansion of both structures and the construction of a second manufacturing building.

Nexus Pharmaceuticals will begin construction in August of 2019 on a $250 million manufacturing complex in Pleasant Prairie, Wis. The multi-phase project will be delivered over the next ten years, enabling Nexus to expand its production capacity for sterile injectable drugs. The first phase comprises an $85 million manufacturing building featuring an advanced isolator system and multiple lyophilization machines. The three-story, 84,450-sf structure was designed by Integrated Project Services and will be built by Turner Construction.

Tergus Pharma began construction in July of 2019 on a cGMP commercial manufacturing facility in Research Triangle Park in North Carolina. An existing 100,000-sf building will undergo renovation to become the company's headquarters, providing production suites, laboratories, offices, packaging lines, and a GMP warehouse. The $35 million project will also include a clinical trial materials manufacturing space and suites for the creation of high-potency compounds and hormones. Completion is expected in early 2020.

ElevateBio has selected DPS Group and TRIA to design ElevateBio BaseCamp, a 108,000-sf cGMP development and manufacturing facility in Waltham. Located in a 430,000-sf office and lab building, the facility will offer integrated R&D, process development, and cGMP manufacturing services for novel therapeutic technologies.

Hewlett Packard (HP) opened the 3D Printing and Digital Manufacturing Center of Excellence in June of 2019 in Barcelona, Spain. Supporting leading-edge research and development in additive manufacturing, the facility provides sophisticated research labs and instrumentation suites as well as a large-scale factory environment for active collaboration with customers and industry partners.

Aldevron will begin construction in August of 2019 on a 14-acre biologics campus in Fargo, N.D., where it is currently headquartered. The first phase comprises a two-story, 189,000-sf facility for the manufacture of plasmid DNA, proteins, mRNA, and antibodies. Increasing Aldevron’s GMP and GMP-Source™ production capacity up to tenfold, the structure will connect to the company's existing GMP facility and is expected to be fully operational by early 2021.

WuXi Biologics began construction in May of 2019 on a $365 million pharmaceutical production facility in Dundalk, Ireland. Sited on 52 acres, the 522,000-sf contract manufacturing center will utilize single-use technologies and processes, enabling cost-effective scale-out and the simultaneous production of multiple batches of varying volumes. Commercial operations are expected to begin in 2022 at the site, which will be the company's first manufacturing plant outside of China.